- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Partnerships and collaborations
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Protein 'gatekeeper' may open door to better malaria treatments
22 August 2018
Walter and Eliza Hall Institute researchers have uncovered a potential new target in the fight to eliminate malaria, a parasitic disease that kills more than 400,000 people annually.
the malaria parasite takes over a red blood cell
The research, led by Dr Danushka Marapana and Professor Alan Cowman, discovered a protein complex essential for the function of the malaria protein plasmepsin V, which their earlier research had also identified as a promising target for antimalarial drugs.
The team hopes that targeting this complex, which is critical for the takeover of red blood cells by the malaria parasite, could lead to the development potential new antimalarial treatments.
At a glance
- New drugs are urgently needed to treat malaria, and our researchers recently developed a potential antimalarial drug that targets the parasite protein plasmepsin V.
- The team have now discovered plasmepsin V replies on the newly identified protein complex, improving the understanding of how this protein enables malaria parasites to survive within red blood cells.
- In the future, drugs that target this complex could potentially be combined with inhibitors of plasmepsin V to provide new antimalarial treatments
Protein gatekeeper
There are many separate compartments within cells, like rooms in a house. The movement of proteins and other molecules between these areas is tightly controlled.
When the malaria parasite invades a red blood cell, it ‘remodels’ the red blood cell, living within its own compartment and moving its own proteins into different parts of the cell, Dr Marapana said.
“Our team recently demonstrated that the protein plasmepsin V is critical for this remodelling by the deadliest malaria parasite, Plasmodium falciparum. Plasmepsin V modifies certain parasite proteins – called PEXEL proteins – so they can be sent into other compartments in the red blood cells,” he said.
Plasmepsin V is located in a compartment within the parasite called the endoplasmic reticulum. PEXEL proteins are located outside this compartment, and until now it was a mystery how the PEXEL proteins reached plasmepsin V.
“Our research showed that a cluster of proteins act as ‘gatekeepers’, recruiting PEXEL proteins to the endoplasmic reticulum where they can be processed by plasmepsin V.”
The research, which was published in the journal Nature Microbiology, also showed that without this complex of proteins, PEXEL proteins couldn’t reach plasmepsin V.
“This discovery explains an important step in how plasmepsin V functions. Plasmepsin V is essential for the survival of P. falciparum parasites in red blood cells, so it is valuable to understand how this complex functions,” Dr Marapana said.
Potential new drug target
Visualisation from WEHI.TV animation
'Malaria Lifecycle Part 1: Human Host'
New drugs for malaria are urgently needed, as parasite strains have emerged that have developed resistance to almost all the leading antimalarials in clinical use. This newly identified complex of proteins, which is critical for parasite survival, may be a new target for antimalarial therapies, Professor Cowman said.
“Teams at our Institute have already developed inhibitors that block the function of P. falciparum plasmepsin V, and this approach shows promise as a new treatment for malaria. We speculate that drugs that prevent PEXEL proteins from engaging plasmepsin V could be another avenue for treating malaria, or could enhance the efficacy of drugs directly targeting plasmepsin V,” he said.
“There are already potential anti-cancer drugs that block a human protein complex similar to the one we have identified in P. falciparum, so we are optimistic that it would be possible to develop a similar drug as a possible antimalarial agent.
“As well as being potential new treatments for malaria on their own, drugs that target the newly identified complex might also be combined with drugs targeting plasmepsin V. A combination of drugs could potentially use less of each drug to kill the malaria parasite, a concept known as synergy. Combining these putative antimalarial drugs could also make it harder for drug resistant parasites to emerge,” Professor Cowman said.
The research was supported by the Australian National Health and Medical Research Council, Howard Hughes Medical Institute, EMBO and the Victorian Government.
Media enquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.
Light microscopy at the Institute's Centre for Dynamic Imaging is giving researchers new insights into the behaviour of a deadly malaria-causing parasite.
This WEHI.TV biomedical animation reconstructs the infection of a human child via mosquito bite, through invasion of cellular tissues including the liver and blood.
Visualisation of the parasite infection inside a pregnant female mosquito.